Business news · Corporate · 27 Apr 2026
IN Healthcare
Sun Pharmaceutical agreed to acquire US-based Organon in an all-cash deal at $14 a share, valuing it at an enterprise value of $11.75 billion. Sun plans to fund it with $2-2.5 billion of internal accruals and $9.25-9.75 billion of debt. The combined company would have revenue of about $12.4 billion, placing Sun among the world's top 25 drugmakers and making it the seventh-largest biosimilars player. Sun's shares rose 6.97% on the NSE to about Rs 1,733.50, their biggest one-day gain since July 30, 2021.
The purchase roughly doubles Sun Pharma's revenue base and deepens its exposure to the US and biosimilars, but it is financed largely with $9.25-9.75 billion of new borrowing, so integration, synergy delivery and debt reduction become the main drivers of Sun's earnings and credit profile. For other listed Indian drugmakers it resets the benchmark for gaining global scale through acquisitions; the direct financial effect on them is small.
Reported by Business Standard — “Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal” ↗ on 27 Apr 2026.
NSE stocks, from the last close on or before 27 Apr 2026 to the close on 16 Oct 2026.
| Sector | Stocks | Median move | Up | vs all stocks |
|---|---|---|---|---|
| Healthcare | 74 | +7.7% | 53 of 74 | +11.3 pts |
| All tracked stocks | 798 | -3.5% | 356 of 798 | — |
| Company | Then | Now | Move |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. SUNPHARMA | ₹1,733.5 | ₹1,758.8 | +1.5% |
After a week with one small new issue, October's fundraising depends almost entirely on Jio Platforms, whose reported size is about twenty times that of Paras Healthcare. In Tonbo Imaging's case all proceeds go to…
Crude below $100 eases the import bill and the input costs of oil marketers, airlines, paints and chemicals, which is why Reliance, IndiGo and Asian Paints were among the gainers. Banks and consumer names moved on…
Two listed groups sit on either side of this. Health and general insurers would pay out less per claim, which is the industry's stated aim: it blames hospital billing inflation for rising claim costs and premiums…
The rebound was narrow: FMCG, consumer durables and PSU banks carried it, while small caps, hospitals and part of IT closed lower. ITC's move followed analyst comments that its response to the cigarette tax increase is…